|Arch Biopartners Inc., of Toronto||Metablok||LSALT peptide||COVID-19||Submitted CTA to Health Canada for a phase II study to prevent lung and kidney inflammation in COVID-19 patients|
|Biosig Technologies Inc., of Westport, Conn., and subsidiary Viralclear Pharmaceuticals Inc.||Merimepodib||Broad-spectrum antiviral||COVID-19||Viralclear submitted IND to FDA for phase II trial|
|Innovent Biologics Inc., of Suzhou, China, and Eli Lilly and Co., of Indianapolis||Tyvyt (sintilimab)||Anti-PD-1 monoclonal antibody||Nonsquamous non-small-cell lung cancer||China’s NMPA accepted the sNDA seeking approval for use in combination with Alimta (pemetrexed, Lilly) and platinum chemo as first-line therapy|
|Janssen Pharmaceutical Cos., of Horsham, Pa.||Simponi Aria (golimumab)||Anti-TNF-alpha biologic for intravenous injection||Polyarticular juvenile idiopathic arthritis||Submitted supplemental BLA to the FDA seeking approval for use in patients, 2 and older, in combination with methotrexate|
|Janssen Pharmaceutical Cos., of Horsham, Pa.||Simponi Aria (golimumab)||Anti-TNF-alpha biologic for intravenous injection||Juvenile psoriatic arthritis||Submitted supplemental BLA to the FDA seeking approval for use in patients, 2 and older, in combination with methotrexate|
|Oryzon Genomics SA, of Madrid||Vafidemstat||Oral, CNS optimized LSD1 inhibitor||COVID-19||Received approval from Spanish drug agency (AEMPS) to conduct phase II study in seriously ill patients|
|Sanofi SA, of Paris||Menquadfi||Meningococcal (groups A, C, Y, W) conjugate vaccine||Meningococcal disease||FDA approved BLA for the prevention of invasive disease in persons 2 and older|
For more information about individual companies and/or products, see Cortellis.